title: Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline.
abstract: Bath-applied monoamines-dopamine (DA), serotonin (5-HT), and noradrenaline (NE)-strongly suppress the perforant path (PP) input to CA1 hippocampal region with very little effect on the Schaffer collaterals (SC) input. The effect of DA action on PP field excitatory postsynaptic potential (fEPSP) has been characterized in detail, but relatively little is known about the NE and 5-HT effects. Here we show that the maximal inhibition of the PP fEPSP by NE is approximately 55%, whereas 5-HT inhibition is weaker ( approximately 35%). The half-maximal inhibitory concentration of both 5-HT and NE is approximately 1 muM. Neither NE nor 5-HT affected paired-pulse facilitation, suggesting that the effect is not presynaptic. This is in contrast to DA, which does have a presynaptic effect. The NE effect was blocked by alpha2 antagonists, whereas the alpha1 antagonist corynanthine and beta-antagonist propranolol were ineffective. The effect of 5-HT was mimicked by the agonist, 5-carboxamidotryptamine maleate (5-CT), and not affected by adrenergic and dopaminergic antagonists. To determine the 5-HT receptors involved, we tested a number of 5-HT antagonists, but none produced a complete suppression of the 5-HT effect. Of these, only the 5-HT7 and 5-HT2 antagonists produced weak but significant inhibition of 5-HT effect. We conclude that NE inhibits the PP fEPSP through postsynaptic action on alpha2-adrenoceptors and that 5-HT7, 5-HT2, and some other receptor may be involved in 5-HT action in PP.
authors.affiliation: Department of Biology and Volen Center for Complex Systems, Brandeis University, Waltham, MA 02454, USA.
authors.forename: Nonna A
authors.initials: NA
authors.lastname: Otmakhova
authors.forename: Jennifer
authors.initials: J
authors.lastname: Lewey
authors.forename: Brent
authors.initials: B
authors.lastname: Asrican
authors.forename: John E
authors.initials: JE
authors.lastname: Lisman
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001572:Benzofurans / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004558:Electric Stimulation / Q000379:methods; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects; D006624:Hippocampus / Q000166:cytology*; D007093:Imidazoles / Q000494:pharmacology; D066298:In Vitro Techniques; D009433:Neural Inhibition / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects; D009474:Neurons / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects; D009638:Norepinephrine / Q000494:pharmacology*; D018408:Patch-Clamp Techniques / Q000379:methods; D019580:Perforant Pathway / Q000187:drug effects* / Q000502:physiology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D012701:Serotonin / Q000494:pharmacology*; D018490:Serotonin Agents / Q000494:pharmacology; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D001572:Benzofurans; D007093:Imidazoles; D018490:Serotonin Agents; D015016:Yohimbine; D012701:Serotonin; D011433:Propranolol; C062597:efaroxan; D004298:Dopamine; D009638:Norepinephrine